阿夫凯泰与美托洛尔对症状性梗阻性HCM超声心动图指标的影响:MAPLE-HCM研究
MAPLE-HCM研究纳入175例症状性梗阻性肥厚型心肌病患者,随机接受阿夫凯泰5-20mg或美托洛尔50-200mg治疗24周,比较单药治疗对心脏结构和功能的影响。与美托洛尔相比,阿夫凯泰显著降低静息和Valsalva左室流出道压差、左房容积指数,改善左室舒张功能指标E/e',并减少二尖瓣收缩期前向运动和反流,但左室射血分数轻度下降。
要点
- 阿夫凯泰较美托洛尔降低静息LVOT-G 30 mmHg、Valsalva LVOT-G 35 mmHg,均P<0.001
- 阿夫凯泰改善左室舒张功能(E/e'下降)并减小左房容积指数和最大室壁厚度
- 阿夫凯泰组LVEF轻度下降(-4%),静息心输出量无显著组间变化
核心结论
- 在症状性梗阻性HCM患者中,阿夫凯泰单药治疗24周较美托洛尔更显著降低LVOT-G和左房容积指数,改善左室舒张功能、二尖瓣收缩期前向运动及二尖瓣反流。
- 阿夫凯泰治疗导致LVEF较美托洛尔轻度下降,但静息心输出量无显著变化。
研究设计与样本
- MAPLE-HCM研究为随机对照试验,纳入175例症状性梗阻性HCM患者。
- 患者接受阿夫凯泰5-20mg或美托洛尔50-200mg滴定治疗,随访24周,系列采集超声心动图。
主要发现
- 与美托洛尔相比,阿夫凯泰降低静息LVOT-G 30 mmHg(95%CI -37至-23,P<0.001)和Valsalva LVOT-G 35 mmHg(95%CI -44至-26,P<0.001)。
- 阿夫凯泰降低左房容积指数7.0 mL/m2(95%CI -9.1至-4.8,P<0.001),改善侧壁E/e' 2.8(95%CI -4.0至-1.6,P<0.001)和室间隔E/e' 3.1(95%CI -4.5至-1.7,P<0.001)。
- 阿夫凯泰使最大室壁厚度减少1.0 mm(95%CI -1.8至-0.2,P=0.02),LVEF下降4%(95%CI -5%至-3%)、整体纵向应变下降1.2%(95%CI -1.8%至-0.5%)、整体环向应变下降2.5%(95%CI -3.7%至-1.3%),均P<0.001。
- 第24周时阿夫凯泰组二尖瓣收缩期前向运动和 mitral regurgitation 显著减少。
临床怎么用
- 对于症状性梗阻性HCM患者,阿夫凯泰单药治疗可较美托洛尔更有效降低LVOT-G并改善舒张功能及二尖瓣反流。
- 使用阿夫凯泰时需监测LVEF变化,尽管静息心输出量无显著影响,LVEF可出现轻度下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Beta-blockers have formed the mainstay of first-line therapy for symptomatic obstructive hypertrophic cardiomyopathy (HCM) for decades. Aficamten, compared with placebo, lowered left ventricular outflow tract gradients (LVOT-G), improved measures of left ventricular (LV) diastolic function, and showed evidence of favorable remodeling when added to standard of care medical therapy in SEQUOIA-HCM. The comparative effectiveness of monotherapy with aficamten vs metoprolol was investigated in MAPLE-HCM. OBJECTIVES: This study evaluated the effect of monotherapy with aficamten compared with metoprolol on cardiac structure and function in participants enrolled in the MAPLE-HCM study. METHODS: Serial echocardiograms and other clinical measures were collected over 24 weeks in participants receiving escalating doses of aficamten 5 to 20 mg or metoprolol 50 to 200 mg. RESULTS: The study enrolled 175 participants (mean age 58 ± 13 years, 42% women, 80% White, 14% Asian). Mean left ventricular ejection fraction (LVEF) was 68% ± 4% with resting and Valsalva LVOT-G of 47 ± 29 mm Hg and 74 ± 33 mm Hg, respectively. Compared with metoprolol, aficamten decreased resting LVOT-G (-30 mm Hg [95% CI: -37 to -23 mm Hg]; P < 0.001) and Valsalva LVOT-G (-35 mm Hg [95% CI: -44 to -26 mm Hg]; P < 0.001); reduced left atrial volume index (left atrial volume index -7.0 mL/m2 [95% CI: -9.1 to -4.8 mL/m2]; P < 0.001); and improved E/e' (lateral E/e' -2.8 [95% CI: -4.0 to -1.6]; P < 0.001; septal E/e' -3.1 [95% CI: -4.5 to -1.7]; P < 0.001). Maximal wall thickness decreased (-1.0 mm [95% CI: -1.8 to -0.2 mm]; P = 0.02). LVEF, absolute LV global longitudinal strain, and absolute global circumferential strain decreased (LVEF -4% [95% CI: -5% to -3%]; global longitudinal strain -1.2% [95% CI: -1.8% to -0.5%]; global circumferential strain -2.5% [95% CI: -3.7% to -1.3%]; all P < 0.001) with no significant change in resting cardiac output between groups. Mitral valve systolic anterior motion and mitral regurgitation significantly decreased with aficamten at week 24. CONCLUSIONS: In addition to lowering Valsalva LVOT-G and left atrial volume index, treatment with aficamten compared with metoprolol over 24 weeks led to improvement in measures of LV diastolic function, mitral valve systolic anterior motion, and mitral regurgitation. Aficamten therapy resulted in modest reduction in LVEF compared with metoprolol. These exploratory findings further support the overall superiority of therapy with aficamten over metoprolol demonstrated in MAPLE-HCM with evidence of favorable changes in multiple echocardiographic measures of cardiac structure and function in patients with symptomatic obstructive HCM. (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM [MAPLE-HCM]; NCT05767346).
引用
- Hegde SM, Wang X, Garcia-Pavia P, et al. Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM. J Am Coll Cardiol. 2025. PMID: 40932433. doi:10.1016/j.jacc.2025.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。